Evidence method
Level · gp.fundamentals.debt_to_revenue
89.93% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ANIP · Dec 31, 2019
ANI PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001104659-20-025744General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
3.21% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
22.09% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
2.47% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
23.32% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
69.42% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
7.92% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
9.59% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
4.46% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History49 statesSelf-history eligible
Sep 30, 20218/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 134.46%
- Current
- 89.93%
- Delta
- -44.53%
- Previous
- 2.97%
- Current
- 3.21%
- Delta
- 0.25%
- Previous
- 42.45%
- Current
- 22.09%
- Delta
- -20.36%
- Previous
- 1.25%
- Current
- 2.47%
- Delta
- 1.22%
- Previous
- 89.94%
- Current
- 23.32%
- Delta
- -66.62%
- Previous
- 70.78%
- Current
- 69.42%
- Delta
- -1.35%
- Previous
- 14.27%
- Current
- 7.92%
- Delta
- -6.36%
- Previous
- 9.70%
- Current
- 9.59%
- Delta
- -0.12%
- Previous
- 4.81%
- Current
- 4.46%
- Delta
- -0.35%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ANIP Fundamental State →Has State · ANI PHARMACEUTICALS INC →Transitioned To · ANIP Fundamental State →Transitioned To · ANIP BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · ANIP CAPEX_INTENSITY_INCREASED →Transitioned To · ANIP CASH_GENERATION_DECREASED →Transitioned To · ANIP GROWTH_INCREASED →Transitioned To · ANIP INVENTORY_PRESSURE_DECREASED →Transitioned To · ANIP MARGIN_DECREASED →Transitioned To · ANIP PROFITABILITY_DECREASED →Transitioned To · ANIP R_AND_D_INTENSITY_DECREASED →Transitioned To · ANIP SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.